Market Overview:
The global noninvasive prenatal diagnostics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for noninvasive prenatal diagnostics due to its accuracy and safety as compared to invasive methods. In addition, the increasing incidence of genetic disorders and rising awareness about noninvasive prenatal diagnostics are also contributing factors for the growth of this market. Based on type, the global noninvasive prenatal diagnostics market can be segmented into services and instruments. The services segment is expected to account for a larger share of the global market than the instruments segment during the forecast period. This can be attributed to factors such as ease of use and low cost as compared to instruments.
Product Definition:
Noninvasive prenatal diagnostics (NIPD) is the umbrella term for a range of techniques that allow for the detection of genetic abnormalities in a fetus without requiring the extraction of fetal tissue. NIPD can be used to detect chromosomal abnormalities, such as Down syndrome, and single-gene disorders, such as cystic fibrosis. The importance of NIPD lies in its ability to provide information about a fetus' health without posing any risk to the mother or unborn child.
Services:
The global services market for noninvasive prenatal diagnostics (NIPD) was valued at USD 1.1 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The key drivers attributing to the growth of this market are increasing awareness about NIPD, technological advancements pertaining to diagnostic procedures, and rising demand for early detection & prevention of genetic disorders in fetus & newborns.
Instrument:
Instruments are used for the collection and analysis of biological or physical parameters. They can be used in clinical, research, and diagnostic settings. In noninvasive prenatal diagnostics (NIPD), instruments such as ultrasound devices play an important role in providing information to healthcare providers about the health of fetus by analyzing external features such as weight, length & head size etc.
The global NIPD market is segmented on the basis of product into ultrasound imaging systems.
Application Insights:
The hospital application segment dominated the global market in 2017. This is due to a large number of hospitals that offer prenatal care and have diagnostic facilities for ultrasound, amniocentesis and chorionic villus sampling (CVS). Moreover, hospitals are considered as the most preferred place for diagnosing pregnancy-related complications.
Hence, majority of pregnant women prefer to undergo diagnostic tests at hospitals due to convenience and availability of services along with an advanced level of expertise in diagnosis. The personal application segment is expected to grow at a lucrative rate during the forecast period owing to increasing awareness about pre-conception health among individuals across various regions including North America, Europe, Asia Pacific and Middle East & Africa.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced products and services, and supportive government initiatives. For instance, in 2014-2015 season, National Public Radio (NPR) carried a series of stories on Fetal Diagnostic Technology that highlighted various ethical issues associated with these tests as well as current state-of-the art procedures available for prenatal diagnosis.
In September 2018, UAB Comprehensive Cancer Centre introduced MaterniT21 program which is an intervention program aimed at reducing maternal mortality rates by focusing on early detection through noninvasive prenatal screening (NPS). Under this NPS includes blood tests for pregnant women that measure levels fetal sex hormones such as testosterone or estradiol along with other factors such as placenta previa or AbNORMAL gene mutation.
Growth Factors:
- Increasing demand for noninvasive prenatal diagnostics due to the increasing incidence of chromosomal abnormalities and genetic disorders.
- Growing awareness about the benefits of early diagnosis and treatment of genetic disorders.
- Technological advancements in noninvasive prenatal diagnostics that are helping to improve accuracy and detection rates.
- Rising demand for noninvasive prenatal testing from pregnant women over the age of 35 years, who are at a higher risk for chromosomal abnormalities and genetic disorders.
Scope Of The Report
Report Attributes
Report Details
Report Title
Noninvasive Prenatal Diagnostics Market Research Report
By Type
Services, Instrument
By Application
Hospital, Personal, Other
By Companies
Natera, Illumina, BGI Diagnosis, Ariosa Diagnostics, Quest Diagnostics, Premaitha Health, NIPD Genetics, Labcorp, Ravgen, LifeCodexx, TrovaGene, Quest Diagnostics, Berry Genomics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Noninvasive Prenatal Diagnostics Market Report Segments:
The global Noninvasive Prenatal Diagnostics market is segmented on the basis of:
Types
Services, Instrument
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Personal, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Natera
- Illumina
- BGI Diagnosis
- Ariosa Diagnostics
- Quest Diagnostics
- Premaitha Health
- NIPD Genetics
- Labcorp
- Ravgen
- LifeCodexx
- TrovaGene
- Quest Diagnostics
- Berry Genomics
Highlights of The Noninvasive Prenatal Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Services
- Instrument
- By Application:
- Hospital
- Personal
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Noninvasive Prenatal Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Noninvasive prenatal diagnostics (NIPD) is a term used to describe a variety of tests that are not invasive and do not require surgery. These tests can help doctors diagnose problems with the baby before they occur, such as birth defects or chromosomal abnormalities.
Some of the major players in the noninvasive prenatal diagnostics market are Natera, Illumina, BGI Diagnosis, Ariosa Diagnostics, Quest Diagnostics, Premaitha Health, NIPD Genetics, Labcorp, Ravgen, LifeCodexx, TrovaGene, Quest Diagnostics, Berry Genomics.
The noninvasive prenatal diagnostics market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Noninvasive Prenatal Diagnostics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Noninvasive Prenatal Diagnostics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Noninvasive Prenatal Diagnostics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Noninvasive Prenatal Diagnostics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Noninvasive Prenatal Diagnostics Market Size & Forecast, 2018-2028 4.5.1 Noninvasive Prenatal Diagnostics Market Size and Y-o-Y Growth 4.5.2 Noninvasive Prenatal Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Noninvasive Prenatal Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Noninvasive Prenatal Diagnostics Market Size Forecast by Type
5.2.1 Services
5.2.2 Instrument
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Noninvasive Prenatal Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Personal
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Noninvasive Prenatal Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Noninvasive Prenatal Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Noninvasive Prenatal Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Noninvasive Prenatal Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Noninvasive Prenatal Diagnostics Market Size Forecast by Type
9.6.1 Services
9.6.2 Instrument
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Personal
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Noninvasive Prenatal Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Noninvasive Prenatal Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Noninvasive Prenatal Diagnostics Market Size Forecast by Type
10.6.1 Services
10.6.2 Instrument
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Personal
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Noninvasive Prenatal Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Noninvasive Prenatal Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Noninvasive Prenatal Diagnostics Market Size Forecast by Type
11.6.1 Services
11.6.2 Instrument
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Personal
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Noninvasive Prenatal Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Noninvasive Prenatal Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Noninvasive Prenatal Diagnostics Market Size Forecast by Type
12.6.1 Services
12.6.2 Instrument
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Personal
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Noninvasive Prenatal Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Noninvasive Prenatal Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Noninvasive Prenatal Diagnostics Market Size Forecast by Type
13.6.1 Services
13.6.2 Instrument
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Noninvasive Prenatal Diagnostics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Personal
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Noninvasive Prenatal Diagnostics Market: Competitive Dashboard
14.2 Global Noninvasive Prenatal Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Natera
14.3.2 Illumina
14.3.3 BGI Diagnosis
14.3.4 Ariosa Diagnostics
14.3.5 Quest Diagnostics
14.3.6 Premaitha Health
14.3.7 NIPD Genetics
14.3.8 Labcorp
14.3.9 Ravgen
14.3.10 LifeCodexx
14.3.11 TrovaGene
14.3.12 Quest Diagnostics
14.3.13 Berry Genomics